{"id":47864,"date":"2020-07-31T06:00:51","date_gmt":"2020-07-31T11:00:51","guid":{"rendered":"https:\/\/www.partnershipagainstcancer.ca\/?post_type=topics&#038;p=47864"},"modified":"2021-01-11T11:19:05","modified_gmt":"2021-01-11T16:19:05","slug":"current-state","status":"publish","type":"topics","link":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/","title":{"rendered":"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada"},"content":{"rendered":"<p>Le cancer du sein est le cancer le plus fr\u00e9quemment diagnostiqu\u00e9 chez les Canadiennes. Gr\u00e2ce aux progr\u00e8s du d\u00e9pistage par mammographie et des traitements, les personnes atteintes d\u2019un cancer du sein pr\u00e9sentent les meilleurs r\u00e9sultats, sur le plan de la survie, parmi toutes celles ayant contract\u00e9 un cancer. Aujourd\u2019hui, 88 % des femmes ayant re\u00e7u un diagnostic de cancer du sein demeureront en vie pendant au moins cinq ans apr\u00e8s la date du diagnostic.<\/p>\n<p>Un diagnostic de cancer du sein d\u00e9bute souvent par une mammographie interpr\u00e9t\u00e9e comme \u00e9tant anormale et devant donner lieu \u00e0 des examens de suivi. En mati\u00e8re de d\u00e9pistage du cancer du sein, le taux de rappel pour anomalie (TRA) est le pourcentage de mammographies interpr\u00e9t\u00e9es comme anormales. Il s\u2019agit d\u2019un important indicateur de la qualit\u00e9 d\u2019un programme de d\u00e9pistage. Si le TRA est trop faible, il y a un risque que certains cancers ne soient pas d\u00e9tect\u00e9s; en revanche, s\u2019il est trop \u00e9lev\u00e9, comme c\u2019est le cas actuellement au Canada, on pourrait demander \u00e0 des personnes, dont on s\u2019apercevra finalement qu\u2019elles n\u2019ont pas de cancer, de passer des examens inutiles.<\/p>\n<div class=\"related-stats blue col-sm-12 col-md-12 col-lg-12 display-left\"><div class=\"stats-header\">100 millions de dollars<\/div>   <div class=\"stats-sub-header\">en examens de suivi inutiles pourraient \u00eatre \u00e9conomis\u00e9s en r\u00e9duisant les TRA canadiens, dans le cadre du d\u00e9pistage du cancer du sein<\/div>\n                    <\/div>\n<h2>Le Canada atteint-il les cibles qu\u2019il s\u2019est fix\u00e9es en mati\u00e8re de TRA?<\/h2>\n<p>Non. Les personnes devant passer des examens de suivi sont trop nombreuses. Depuis plus d\u2019une d\u00e9cennie, les TRA canadiens sont sup\u00e9rieurs aux cibles nationales :<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47971\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png\" alt=\"depistages initiaux and depistages subsequents\" width=\"700\" height=\"430\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png 700w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR-300x184.png 300w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/text-description-chart-target-versus-actual-abnormal-call-rates-cancer-detection-rates\/\"><span style=\"font-size: small;\">Description textuelle<\/span><\/a><\/p>\n<p style=\"text-align: left;\">Les TRA varient, selon les provinces et les territoires, mais la plupart des programmes de d\u00e9pistage organis\u00e9 du cancer du sein pr\u00e9sentent des TRA sup\u00e9rieurs aux cibles nationales. Entre 2008 et 2012, les TRA pour les d\u00e9pistages subs\u00e9quents sont pass\u00e9s de 6,1 \u00e0 7,4 %. <strong>En 2017, ils atteignaient 7,8 %<\/strong>. Des augmentations similaires ont \u00e9galement \u00e9t\u00e9 observ\u00e9es pour les TRA relatifs aux d\u00e9pistages initiaux.<\/p>\n<p>En d\u00e9pit de cette hausse des TRA, les taux de d\u00e9tection de cancers (TDC) sont rest\u00e9s stables. On a \u00e9galement assist\u00e9 \u00e0 une diminution des valeurs pr\u00e9dictives positives (VPP), qui mesurent la probabilit\u00e9 qu\u2019une personne, rappel\u00e9e pour des examens suppl\u00e9mentaires, ait effectivement un cancer.<\/p>\n<p>Au Canada, des TRA \u00e9lev\u00e9s, des TDC stables et des VPP faibles signifient que <strong>les programmes de d\u00e9pistage du cancer du sein orientent un plus grand nombre de personnes vers des examens de suivi, sans pour autant d\u00e9tecter plus de cancers<\/strong>. Ces examens de suivi constituent une importante source de stress et peuvent nuire au bien-\u00eatre physique et psychologique de la personne qui les subit. Ils ont \u00e9galement des r\u00e9percussions sur le syst\u00e8me de sant\u00e9, mobilisant des ressources, au d\u00e9triment d\u2019autres personnes qui pourraient v\u00e9ritablement avoir besoin de ces examens.<\/p>\n<h2>Taux de rappel pour anomalie pour les d\u00e9pistages subs\u00e9quents, par province ou par territoire<\/h2>\n<p>Les TRA, aussi bien pour les d\u00e9pistages initiaux que pour les d\u00e9pistages subs\u00e9quents, sont \u00e9lev\u00e9s depuis 2013.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47974\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-by-Prov-Terr-FR.png\" alt=\"graphique sur les d\u00e9pistages subs\u00e9quents du cancer du sein par province et territoire\" width=\"700\" height=\"538\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-by-Prov-Terr-FR.png 700w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-by-Prov-Terr-FR-300x231.png 300w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: small;\"><span class=\"TextRun SCXW217588839 BCX0\" lang=\"FR-CA\" xml:lang=\"FR-CA\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW217588839 BCX0\">Au Canada, le TRA pour les d\u00e9pistages subs\u00e9quents \u00e9tait de\u202f7,6\u202f% en\u202f2013-2014 et de\u202f7,8\u202f% en\u202f2017. <\/span><\/span><br \/>\n<a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/text-description-graph-subsequent-breast-cancer-screens-province-territory\/\">Description textuelle<\/a><\/span><\/p>\n<h2>Quel est l\u2019effet d\u2019une r\u00e9duction des TRA?<\/h2>\n<p>Si l\u2019on r\u00e9ussissait \u00e0 abaisser les TRA pour les d\u00e9pistages subs\u00e9quents \u00e0 6 % d\u2019ici 2029, le Canada pourrait \u00e9viter :<\/p>\n<ul>\n<li>310 000 mammographies diagnostiques;<\/li>\n<li>250 000 \u00e9chographies;<\/li>\n<li>46 000 biopsies.<\/li>\n<\/ul>\n<p>Au total, <strong>110 millions de dollars en examens de suivi inutiles<\/strong> pourraient \u00eatre consacr\u00e9s \u00e0 d\u2019autres domaines en ayant besoin.<\/p>\n<h2>TRA dans le monde<\/h2>\n<p>Les TRA pour le d\u00e9pistage du cancer du sein sont plus \u00e9lev\u00e9s au Canada qu\u2019en Australie et que dans la plupart des programmes de d\u00e9pistage europ\u00e9ens. Le TDC du Canada est comparable \u00e0 celui de l\u2019Europe et inf\u00e9rieur \u00e0 celui de l\u2019Australie<\/p>\n<h3><strong>Comparaison internationale des taux de rappel pour anomalie (TRA)<\/strong><\/h3>\n<p>Comparaison internationale des TRA dans le d\u00e9pistage du cancer du sein, pour les d\u00e9pistages initiaux et subs\u00e9quents<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47979\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-ACR-FR.png\" alt=\"TRAs internationaux\" width=\"700\" height=\"222\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-ACR-FR.png 700w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-ACR-FR-300x95.png 300w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/text-description-international-abnormal-call-rates\/\"><span style=\"font-size: small;\">Description textuelle<\/span><\/a><\/p>\n<h3>Comparaison internationale des taux de d\u00e9tection de cancers (TDC)<\/h3>\n<p>Comparaison internationale des TDC pour 1 000 d\u00e9pistages du cancer du sein, pour les d\u00e9pistages initiaux et subs\u00e9quents<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47983\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-CDR-FR.png\" alt=\"TDCs internationaux\" width=\"700\" height=\"194\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-CDR-FR.png 700w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/International-CDR-FR-300x83.png 300w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/text-description-international-cancer-detection-rates\/\"><span style=\"font-size: small;\">Description textuelle<\/span><\/a><\/p>\n<h2>Lignes directrices internationales en mati\u00e8re de TRA<\/h2>\n<p>Les lignes directrices en mati\u00e8re de TRA cibles acceptables varient d\u2019un pays \u00e0 l\u2019autre. La cible canadienne en mati\u00e8re de TRA se situe dans la fourchette des cibles \u00e9tablies dans d\u2019autres pays dot\u00e9s de syst\u00e8mes de sant\u00e9 et de programmes de d\u00e9pistage comparables.<\/p>\n<table class=\"table table-bordered\">\n<thead>\n<tr class=\"active\">\n<tr>\n<th width=\"328\"><strong>Lignes directrices<\/strong><\/th>\n<th width=\"100\"><strong>D\u00e9pistage initial<\/strong><\/th>\n<th width=\"100\"><strong>D\u00e9pistage subs\u00e9quent<\/strong><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"328\">TRA national canadien cible<\/td>\n<td width=\"100\">&lt; 10 %<\/td>\n<td width=\"100\">&lt; 5 %<\/td>\n<\/tr>\n<tr>\n<td width=\"328\">Cible en mati\u00e8re de taux de rappel \u00e9nonc\u00e9e dans les European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis<\/td>\n<td width=\"100\">&lt; 7 % (acceptable)<br \/>\n&lt; 5 % (souhaitable)<\/td>\n<td width=\"100\">&lt; 5 % (acceptable)<br \/>\n&lt; 3 % (souhaitable)<\/td>\n<\/tr>\n<tr>\n<td width=\"328\">Cible en mati\u00e8re de taux d\u2019orientation pour une \u00e9valuation du National Health Service Breast Screening Programme du Royaume-Uni<\/td>\n<td width=\"100\">&lt; 10 % (acceptable)<br \/>\n&lt; 7 % (r\u00e9alisable)<\/td>\n<td width=\"100\">&lt; 7 % (acceptable)<br \/>\n&lt; 5 % (r\u00e9alisable)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Document \u00e0 t\u00e9l\u00e9charger<\/strong><\/p>\n<div class=\"documents col-md-12\"><div>\n                                <i class=\"fas fa-file-pdf document-icon\"><\/i>\n                                <div class=\"document-details\">\n                                    <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Framework-for-action-ACR-breast-screening-FR.pdf\" target=\"_blank\">Cadre d'action pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein<\/a><p class=\"file-information\">Taille du fichier 6 MB<\/p>         <\/div>\n                            <\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le cancer du sein est le cancer le plus fr\u00e9quemment diagnostiqu\u00e9 chez les Canadiennes. Gr\u00e2ce aux progr\u00e8s du d\u00e9pistage par mammographie et des traitements, les personnes atteintes d\u2019un cancer du sein pr\u00e9sentent les meilleurs r\u00e9sultats, sur le plan de la survie, parmi toutes celles ayant contract\u00e9 un cancer. Aujourd\u2019hui, 88 % des femmes ayant re\u00e7u [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":47860,"menu_order":1,"template":"","topics_tags":[],"type-of-care":[],"cancer-continuum":[],"cancer-system-measurement":[],"dbt-cancer-site":[],"dbt-risk-factors":[],"dbt-population-characteristics":[],"class_list":["post-47864","topics","type-topics","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canadian Partnership Against Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada - Canadian Partnership Against Cancer\" \/>\n<meta property=\"og:description\" content=\"Le cancer du sein est le cancer le plus fr\u00e9quemment diagnostiqu\u00e9 chez les Canadiennes. Gr\u00e2ce aux progr\u00e8s du d\u00e9pistage par mammographie et des traitements, les personnes atteintes d\u2019un cancer du sein pr\u00e9sentent les meilleurs r\u00e9sultats, sur le plan de la survie, parmi toutes celles ayant contract\u00e9 un cancer. Aujourd\u2019hui, 88 % des femmes ayant re\u00e7u [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Partnership Against Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-11T16:19:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@cancerstratca\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/\",\"name\":\"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada - Canadian Partnership Against Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ACR-blue-chart-FR.png\",\"datePublished\":\"2020-07-31T11:00:51+00:00\",\"dateModified\":\"2021-01-11T16:19:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ACR-blue-chart-FR.png\",\"contentUrl\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ACR-blue-chart-FR.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/current-state\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Topics\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/topics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\",\"url\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/\",\"name\":\"Canadian Partnership Against Cancer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canadian Partnership Against Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/","og_locale":"fr_FR","og_type":"article","og_title":"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada - Canadian Partnership Against Cancer","og_description":"Le cancer du sein est le cancer le plus fr\u00e9quemment diagnostiqu\u00e9 chez les Canadiennes. Gr\u00e2ce aux progr\u00e8s du d\u00e9pistage par mammographie et des traitements, les personnes atteintes d\u2019un cancer du sein pr\u00e9sentent les meilleurs r\u00e9sultats, sur le plan de la survie, parmi toutes celles ayant contract\u00e9 un cancer. Aujourd\u2019hui, 88 % des femmes ayant re\u00e7u [&hellip;]","og_url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/","og_site_name":"Canadian Partnership Against Cancer","article_publisher":"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/","article_modified_time":"2021-01-11T16:19:05+00:00","og_image":[{"url":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@cancerstratca","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/","url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/","name":"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada - Canadian Partnership Against Cancer","isPartOf":{"@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/#primaryimage"},"image":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/#primaryimage"},"thumbnailUrl":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png","datePublished":"2020-07-31T11:00:51+00:00","dateModified":"2021-01-11T16:19:05+00:00","breadcrumb":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/#primaryimage","url":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png","contentUrl":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/ACR-blue-chart-FR.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/current-state\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Topics","item":"https:\/\/www.partnershipagainstcancer.ca\/topics\/"},{"@type":"ListItem","position":2,"name":"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein","item":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/"},{"@type":"ListItem","position":3,"name":"Situation actuelle en mati\u00e8re de TRA dans le contexte du d\u00e9pistage du cancer du sein au Canada"}]},{"@type":"WebSite","@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website","url":"https:\/\/dev.partnershipagainstcancer.ca\/","name":"Canadian Partnership Against Cancer","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.partnershipagainstcancer.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/47864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/types\/topics"}],"author":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/users\/24"}],"up":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/47860"}],"wp:attachment":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=47864"}],"wp:term":[{"taxonomy":"topics_tags","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics_tags?post=47864"},{"taxonomy":"type-of-care","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/type-of-care?post=47864"},{"taxonomy":"cancer-continuum","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-continuum?post=47864"},{"taxonomy":"cancer-system-measurement","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-system-measurement?post=47864"},{"taxonomy":"dbt-cancer-site","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-cancer-site?post=47864"},{"taxonomy":"dbt-risk-factors","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-risk-factors?post=47864"},{"taxonomy":"dbt-population-characteristics","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-population-characteristics?post=47864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}